XYLOCAINE SPECIAL ADHESIVE ointment

MIMS Revision Date: 01 December 2024

1 Name of Medicine

Lidocaine.

2 Qualitative and Quantitative Composition

Each gram of Xylocaine Special Adhesive contains lidocaine base 100 mg as the active ingredient.
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Xylocaine Special Adhesive is formulated to adhere to moist oral mucosa and provide topical anaesthesia. It is a white to slightly yellow ointment.

4 Clinical Particulars

4.1 Therapeutic Indications

Surface anaesthesia of the gums prior to injection, before scaling and in conjunction with the fitting of new dentures or orthodontic appliances.
Temporary relief of pain associated with removal of deciduous teeth.

4.2 Dose and Method of Administration

As with any local anaesthetic, reactions and complications are best averted by employing the minimal effective dosage. Debilitated or elderly patients and children should be given doses commensurate with their age and physical condition.
The dose of topical lidocaine should be taken into consideration in estimating the total dose of lidocaine if parenteral lidocaine is to be administered concomitantly.
The following dosage recommendations should be regarded as a guide. The clinician's experience and knowledge of the patient's physical status are of importance in calculating the required dose.
Adults. The maximum single recommended dose of Xylocaine Special Adhesive is 2.5 g, containing 250 mg of lidocaine base (approximately equivalent to 300 mg lidocaine hydrochloride). This is roughly equivalent to squeezing a 7.5 cm length of Special Adhesive from the tube. Not more than 8.5-10 g of the Special Adhesive should be administered in any 24 hour period.
Children. In children less than 12 years of age, the maximum single recommended dose should not exceed 0.05 g ointment/kg bodyweight (corresponding to lidocaine 5 mg/kg bodyweight). Not more than three doses should be administered in a 24 hour period.
The Special Adhesive should be applied in a thin layer for adequate control of symptoms.
In dentistry, apply to previously dried oral mucosa, allow at least 3-5 minutes for anaesthesia to become effective. When inserting new dentures, apply to all denture surfaces contacting mucosa.

4.3 Contraindications

Known history of hypersensitivity to lidocaine or other local anaesthetics of the amide type or to other components of the ointment.

4.4 Special Warnings and Precautions for Use

Warning. Excessive dosage, or short intervals between doses, can result in high levels of lidocaine or its metabolites and serious adverse effects. Patients should be instructed to strictly adhere to the recommended dosage and administration guidelines. The management of serious adverse reactions may require the use of resuscitative equipment, oxygen and other resuscitative drugs.
Patients should not exceed the recommended dose or use Xylocaine Special Adhesive for prolonged periods except on the advice of their physician or dentist.
The lowest dose that results in effective anaesthesia should be used to avoid high plasma levels and serious adverse effects. Tolerance to elevated blood levels varies with the status of the patient.
Dosage reduction. Debilitated, elderly and/or acutely ill patients and children should be given reduced doses commensurate with their age and physical status.
Excessive absorption. Absorption from mucous membranes is relatively high, especially in the bronchial tree. This should be taken into consideration when the Special Adhesive is used in children for treatment of large areas. Because of the possibility of significant systemic absorption, Xylocaine Special Adhesive should be used with caution in patients with traumatised mucosa and/or sepsis in the region of the proposed application.
If the dose or site of administration is likely to result in high blood levels, lidocaine, in common with other local anaesthetics, should be used with caution in patients with epilepsy, impaired cardiac conduction, bradycardia, impaired hepatic function and in severe shock.
Antiarrhythmic drugs class III. Patients treated with antiarrhythmic drugs class III (e.g. amiodarone) should be kept under close surveillance and ECG monitoring considered, since cardiac effects may be additive.
Eating and drinking. The use of topical anaesthetic agents in the oral cavity may interfere with swallowing and thus enhance the danger of aspiration of food or drink. For this reason, food or drink should not be ingested within 60 minutes of using local anaesthetics in the mouth or throat area. Numbness of the tongue or buccal mucosa may increase the danger of biting or heat trauma. Food, chewing gum or hot drinks should not be taken while the mouth or throat area is anaesthetised.
Malignant hyperthermia. Many drugs used during the conduct of anaesthesia are considered potential triggering agents for familial malignant hyperthermia. It has been shown that the use of amide local anaesthetics in malignant hypothermia patients is generally safe, but cases of malignant hyperthermia have occasionally been documented after use.
Sterile instruments. Xylocaine Special Adhesive is not intended for use with sterile instruments.
Use in hepatic impairment. See Section 4.4 Special Warnings and Precautions for Use, Excessive absorption.
Use in the elderly. See Section 4.2 Dose and Method of Administration.
Paediatric use. See Section 4.2 Dose and Method of Administration.
Effects on laboratory tests. No data available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Antiarrhythmic drugs. Lidocaine should be used with caution in patients receiving other local anaesthetics or agents structurally related to local anaesthetics, e.g. antiarrhythmic drugs such as mexiletine, since the toxic effects are additive.
Specific interaction studies with lidocaine and antiarrhythmic drugs class III (e.g. amiodarone) have not been performed, but caution is advised.
Enzyme inducing drugs. Cimetidine has been shown to reduce clearance of IV administered lidocaine. Caution should be taken if administered concurrently with lidocaine.
Phenytoin and other antiepileptic drugs such as phenobarbitone, primidone and carbamazepine appear to enhance the metabolism of lidocaine but the significance of this effect is not known. Phenytoin and lidocaine have additive cardiac depressant effects.

4.6 Fertility, Pregnancy and Lactation

Effects on fertility. No data available.
Use in pregnancy. (Category A)
Lidocaine crosses the placental barrier and may be taken up by foetal tissues. When used for surface anaesthesia, lidocaine blood levels after normal doses are low so little drug is available for placental transfer.
There are, however, no adequate and well-controlled studies in pregnant women. Reproduction studies have been performed in rats at doses of 500 mg/kg/day and have revealed no evidence of harm to the foetus caused by lidocaine.
It is reasonable to assume that a large number of pregnant women and women of child-bearing age have used lidocaine. No specific disturbances to the reproduction process have so far been reported.
Lidocaine is not contraindicated in labour and delivery.
Use in lactation. Lidocaine enters breast milk, but in such small quantities that there is generally no risk of affecting the child at therapeutic dose levels.

4.7 Effects on Ability to Drive and Use Machines

Depending on the dose, local anaesthetics may have a very mild effect on mental function and may temporarily impair locomotion and coordination. With the recommended doses of lidocaine ointment adverse effects on the CNS are unlikely.
Xylocaine Special Adhesive is probably porphyrinogenic and should only be prescribed to patients with acute porphyria on strong or urgent indications. Appropriate precautions should be taken for all porphyric patients.

4.8 Adverse Effects (Undesirable Effects)

Reporting suspected adverse effects. Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.
Systemic adverse reactions are rare and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy or reduced tolerance on the part of the patient. Such reactions are systemic in nature and involve the central nervous system and/or the cardiovascular system.
Central nervous system. CNS reactions are excitatory and/or depressant and may be characterised by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness and, possibly, respiratory arrest. The excitatory reactions may be brief or may not occur at all, in which case the first manifestations of toxicity may be drowsiness, progressing to unconsciousness and respiratory arrest.
Drowsiness following administration of lidocaine is usually an early sign of a high blood level of the drug and may occur as a result of rapid absorption.
Cardiovascular. Cardiovascular reactions are usually depressant and may be characterised by hypotension, myocardial depression, bradycardia and possibly cardiac arrest.
Allergic reactions. Allergic reactions may occur as a result of sensitivity either to the local anaesthetic agent or to other ingredients in the formulation. Allergic reactions as a result of sensitivity to lidocaine are rare (< 0.1%). The detection of sensitivity by skin testing is of doubtful value.
The extremely rare cases of allergy to local anaesthetic preparations have included bronchospasm, chest pain, dyspnoea, pruritus, rash, rhinitis, increased sweating, urticaria, sleepiness, dizziness, paraesthesia, oedema and, in the most severe instances, anaphylactic shock.

4.9 Overdose

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).
Management of local anaesthetic emergencies. The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient's state of consciousness after each local anaesthetic administration. At the first sign of change, oxygen should be administered.
Treatment. If convulsions occur then immediate attention is required for the maintenance of a patent airway and assisted or controlled ventilation with oxygen, via a positive airway pressure delivery system mask. Adequacy of the circulation should then be evaluated, bearing in mind that drugs used to treat convulsions depress the circulation when administered IV. Should convulsions persist despite adequate respiratory support and if the status of the circulation permits, appropriate anticonvulsant medication such as an ultra short acting barbiturate (e.g. thiopental) or a benzodiazepine (e.g. diazepam), may be administered IV. The clinician should be familiar with these anticonvulsant drugs prior to use of local anaesthetics.
Dialysis is of negligible value in the treatment of acute overdosage with lidocaine.

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action. Lidocaine, the active ingredient of Xylocaine Special Adhesive, stabilises the neuronal membrane and prevents the initiation and conduction of nerve impulses, thereby effecting local anaesthetic action.
The onset of action of Xylocaine Special Adhesive occurs within 3-5 minutes on mucous membrane and the effect lasts for approximately 15-20 minutes. It is ineffective when applied to intact skin.
Clinical trials. No data available.

5.2 Pharmacokinetic Properties

Absorption. Lidocaine may be absorbed following topical administration to mucous membranes, its rate of absorption and amount of dose absorbed depending upon concentration and total dose administered, the specific site of application and duration of exposure. In general, the rate of absorption occurs most rapidly after intratracheal administration. Lidocaine is well absorbed from the gastrointestinal tract, but little intact drug appears in the circulation because of biotransformation in the liver.
Metabolism. Lidocaine is metabolised rapidly by the liver, and metabolites and unchanged drug are excreted by the kidney.
Excessive blood levels may cause changes in cardiac output, total peripheral resistance and mean arterial pressure. These changes may be attributable to a direct depressant effect of the anaesthetic agent on various components of the cardiovascular system.
Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage and conjugation. The pharmacological/ toxicological actions of the metabolites are similar to, but not less potent than, those of lidocaine. Approximately 90% of lidocaine is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline.
The plasma binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of free base 1 to 4 microgram/mL, 60 to 80% of lidocaine is protein bound. Binding is also dependent on the plasma concentrations of the alpha-1-acid glycoprotein.
Lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion.
Studies of lidocaine metabolism following IV bolus injection have shown that the elimination half-life is usually 1.5 to 2 hours. The half-life may be prolonged 2-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine kinetics, but may increase the accumulation of metabolites.
Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above free base 6.0 microgram/mL. In the rhesus monkey arterial blood levels of 18 to 21 microgram/mL have been shown to be the threshold for convulsive activity.

5.3 Preclinical Safety Data

Genotoxicity. Genotoxicity tests with lidocaine are inconclusive. In genotoxicity studies, a metabolite of lidocaine, 2,6-xylidine, showed evidence of activity in some tests but not in other tests.
Carcinogenicity. This metabolite of lidocaine, 2,6-xylidine, has been shown to have carcinogenic potential (nasal and subcutaneous tumours) in preclinical toxicological studies evaluating chronic exposure.

6 Pharmaceutical Particulars

6.1 List of Excipients

Carmellose sodium, macrogol 1500, macrogol 300, macrogol 400, propylene glycol, spearmint oil.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

6.4 Special Precautions for Storage

Store below 25°C.

6.5 Nature and Contents of Container

15 g tube.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of by taking to your local pharmacy.

6.7 Physicochemical Properties

The molecular formula of lidocaine is C₁₄H₂₂N₂O. The molecular weight is 234.3.
Chemical structure.

CAS number. 137-58-6.

7 Medicine Schedule (Poisons Standard)

S2- Pharmacy Medicine.

Date of First Approval

13 August 1991

Date of Revision

18 October 2024

Summary Table of Changes